Sun Pharmaceutical Industries Ltd.
SUNPHARMA · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,147.42.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%14.7%
- ✓Low debt (D/E < 0.5)0.06x
- ✓Positive free cash flow
- ✓Revenue growth > 10%13%
- ✓Earnings growing26%
- ✓Net margin ≥ 10%19.6%
- ✓Current ratio > 1.52.82
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 12.18
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (19.6%).
- •Financially solid — Altman Z 12.18.
Weaknesses
- •Weak Piotroski score (3/9).
Opportunities
- •Earnings growing (26% YoY).
- •Revenue growing (13% YoY).
- •Trading in our value buy zone versus sector peers.
Threats
- •Trades ~21% above our estimated fair value.
About Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychia
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.